In this case, this bioequivalence has to be demonstrated by a set of physicochemical (determination of the molecular weight of the intact molecules and light chains, the sequence of N-terminal pep-tides, the degree of oxidation by mass spectrometry, and the size and charge of the molecule as determined by dynamic light scattering) and biological methods as required by regulatory authorities for characterization of Mabs [11]. As mAb-Racotumomab is used as an adjuvated vaccine additional characteristics should be taken into account.In this study, we present the detailed molecular and immunological characterization of mAb-Racotumomab obtained by two different production methods in two scales in order to determine the impact of the manufacturing process in vaccine performance.